GLP-1 Plate / Mounjaro diet plan: eating well on tirzepatide for type 2 diabetes
Mounjaro diet plan: eating well on tirzepatide for type 2 diabetes
Updated October 2026 · Based on FDA prescribing information and the 2025 joint nutrition advisory
Mounjaro (tirzepatide) is a once-weekly GIP and GLP-1 receptor agonist from Eli Lilly, labeled for adults with type 2 diabetes. Eating on Mounjaro means two things at once: smaller meals because appetite drops, and steady meals because blood sugar still matters. Here is what the label says and how to eat around it.
What the Mounjaro label says
- Indication: to improve blood sugar control in adults with type 2 diabetes, as an "adjunct to diet and exercise". That means your diabetes eating plan still applies.
- Stomach side effects: listed below from the label's Table 1.
- Reports after approval: the label lists ileus (bowel slowdown), intestinal obstruction and "severe constipation including fecal impaction" among postmarketing reports. Severe constipation needs medical attention.
Side effect rates in the label
Mounjaro label, Table 1 (type 2 diabetes trials), percentage of patients. Dose columns identify the trial groups only; your prescriber decides your dose.
| Reaction | Placebo / 5 mg / 10 mg / 15 mg |
|---|---|
| Nausea | 4 / 12 / 15 / 18 |
| Diarrhea | 9 / 12 / 13 / 17 |
| Decreased appetite | 1 / 5 / 10 / 11 |
| Vomiting | 2 / 5 / 5 / 9 |
| Constipation | 1 / 6 / 6 / 7 |
| Dyspepsia (indigestion) | 3 / 8 / 8 / 5 |
| Abdominal pain | 4 / 6 / 5 / 5 |
Low blood sugar: the meal-plan issue that matters most
Tirzepatide on its own is not the main concern; the combination is. The tirzepatide label for Zepbound (same medicine as Mounjaro) states that use "with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia", and that the dose of insulin or the secretagogue (such as a sulfonylurea) may need to be lowered. That is a prescriber decision. In its type 2 diabetes study, blood glucose under 54 mg/dL occurred in 4.2% of patients versus 1.3% on placebo, and in 10.3% of those also on a sulfonylurea.
What it means for your plate:
- Do not skip meals or start a very low-calorie day without talking to your care team.
- Keep meals at consistent times, as the 2025 joint advisory recommends.
- Know the signs listed in the Medication Guides: shakiness, sweating, dizziness, hunger, confusion, fast heartbeat, headache, irritability. Ask your care team what to keep on hand.
The nutrition priorities
The label gives no food rules. The 2025 joint advisory (American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, The Obesity Society) is the clearest guide for people on GLP-1 therapy:
| Protein at each meal | Eaten first. The advisory mentions 1.2 to 1.6 g/kg/day proposed during active weight reduction, or 80 to 120 g/day. Ask about kidney function first. See how much protein. |
|---|---|
| Carbohydrate quality | Whole grains, beans, fruits and vegetables rather than refined grains, added sugars and sugar-sweetened drinks. |
| Small, regular meals | "Regular, small meals at consistent times"; avoid becoming overly hungry and avoid large meals. |
| Fiber, gradually | From foods, with fluids. Helpful for constipation; go easy in the first days if nauseous. |
| Fluids | Adequate fluids every day. Vomiting and diarrhea raise the risk of dehydration. |
| Alcohol | Minimal: it may worsen nausea and reflux. Discuss alcohol and blood sugar with your care team. |
For a food list, see what to eat on tirzepatide; the same foods apply. For what to limit, see foods to avoid.
Diabetes nutrition therapy is covered
The 2025 joint advisory notes that Medicare covers medical nutrition therapy by a registered dietitian for diabetes (3 hours the first year, 2 hours each year after). Ask your doctor for a referral: a dietitian can match your meals to your medicines and glucose readings.
Want a structured start? Try the free 1-day meal plan or the 4-week PDF, and review them with your diabetes team.